PharmaResearch
파마리서치 · 214450
Health Care Pharmaceuticals · KOSDAQ
Market cap US$2.2B (₩3T)
Overview
PharmaResearch makes injectable and topical products designed to help the body repair damaged tissue, using active ingredients extracted and purified from salmon DNA.
Its products, which include regenerative medicines, medical devices for skin improvement, and joint-injection treatments, are supplied to medical and aesthetic markets in South Korea and exported to Asia, Europe, and North America. Listed on KOSDAQ, South Korea's tech and small-cap board, the company's core business centres on its proprietary PDRN and PN technology platform, from which it develops products across pharmaceuticals, medical devices, and cosmetics.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$189.1M
- FY2024US$253.7M
- FY2025US$388.6M
Operating profit
- FY2023US$66.9M
- FY2024US$91.3M
- FY2025US$155.4M
Net income
- FY2023US$56M
- FY2024US$64.5M
- FY2025US$121.9M
Key ratios (FY2025)
Why it matters
PharmaResearch operates a subsidiary, PharmaResearch Bio, that runs a dedicated botulinum-toxin manufacturing facility and holds both domestic and export approvals for its toxin product.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?